Skip to main content

Table 1 Repeated measure ANOVA results and post-hoc means of the physicochemical conditions to all treatments throughout time

From: Multi-domain probiotic consortium as an alternative to chemical remediation of oil spills at coral reefs and adjacent sites

Parameters   F value p value Post-Hoc (Mean ± SE)
pH Time 2.03 0.14  
  Treatments 32.02 < 0.0001  
  Time:Treatments 0.58 0.86  
  Post-hoc comparison    Corexit 9500 ( 8.05 ± 0.04)
     oWSF + Corexit 9500 (7.99 ± 0.04)
     oWSF + pBMC-BC + Corexit 9500 (8.06 ± 0.04)
     oWSF (8.34 ± 0.04)
     pBMC-BC (8.54 ± 0.04)
     oWSF + pBMC-BC (8.61 ± 0.04)
     Control (8.47 ± 0.04)
DOC Time 11.24 < 0.001  
  Treatments 1.51 0.21  
  Time:Treatments 1.22 0.29  
  Post-hoc comparison    T0 (3.24 μg/mL ± 0.26)
     T1 (4.44 mg/mL ± 0.26)
     T2 (4.53 μg/mL ± 0.26)
Salinity Time 78.9 < 0.0001  
  Treatments 2.8 0.03  
  Time:Treatments 1.6 0.11  
  Post-hoc comparison    T0 (36.22 mg/L ± 0.07)
     T1 (36.17 mg/L ± 0.07)
     T2 (37.25 mg/L ± 0.07)
     Control (36.70 mg/L ± 0.12)
     oWSF (36.42 mg/L ± 0.12)
     pBMC-BC (36.74 mg/L ± 0.12)
     Corexit 9500 (36.60 mg/L ± 0.12)
     oWSF + pBMC-BC (36.20 mg/L ± 0.14)
     oWSF + Corexit 9500 (36.38 mg/L ± 0.12)
     pBMC-BC + Corexit 9500 (36.85 mg/L ± 0.12)
     oWSF + pBMC-BC + Corexit 9500 (36.47 mg/L ± 0.12)
Ammonium Time 14.86 < 0.0001  
  Treatments 1.33 0.28  
  Time:Treatments 1.07 0.41  
  Post-hoc comparison    T0 (28.10 μg/L ± 19.22)
     T1 (160.09 μg/L ± 19.22)
     T2 (99.83 μg/L ± 19.22)
Nitrate Time 6.88 0.002  
  Treatments 0.35 0.92  
  Time:Treatments 0.72 0.74  
  Post-hoc comparison    T0 (6.56 μg/L ± 10.76)
     T1 (58.11 μg/L ± 10.76)
     T2 (34.65 μg/L ± 10.76)
Phosphate Time 20.21 < 0.0001  
  Treatments 5.59 < 0.001  
  Time:Treatments 3.37 < 0.001  
  Post-hoc comparison    Control in T0 (18.65 μg/L ± 23.19), T1 (61.80 μg/L ± 23.19) and T2 (33.82 μg/L ± 23.19)
     oWSF in T0 (13.96 μg/L ± 23.19), T1 (25.24 μg/L ± 23.19) and T2 (17.26 μg/L ± 23.19)
     pBMC-BC in T0 (5.97 μg/L ± 23.19), T1 (51.55 μg/L ± 23.19) and T2 (70.67 μg/L ± 23.19)
     Corexit 9500 in T0 (3.22 μg/L ± 23.19), T1 (234.27 μg/L ± 23.19) and T2 (136.47 μg/L ± 23.19)
     oWSF + pBMC-BC in T0 (6.76 μg/L ± 23.19), T1 (56.20 μg/L ± 23.19) and T2 (97.50 μg/L ± 23.19)
     oWSF + Corexit 9500 in T0 (0 μg/L ± 23.19), T1 (83.35 μg/L ± 23.19) and T2 (53.00 μg/L ± 23.19)
     pBMC-BC + Corexit 9500 in T0 (3.22 μg/L ± 23.19), T1 (3.77 μg/L ± 23.19) and T2 (109.82 μg/L ± 23.19)
     oWSF + pBMC-BC + Corexit 9500 in T0 (3.77 μg/L ± 23.19), T1 (78.75 μg/L ± 23.19) and T2 (34.20 μg/L ± 23.19)
PAH Time 7.86 0.001  
  Treatments 20.86 < 0.0001  
  Time:Treatments 3.31 0.001  
  Post-hoc comparison    Control in T0 (1.63 μg/L ± 467.05), T1 (0.48 μg/L ± 467.05) and T2 (0.58 μg/L ± 467.05)
     oWSF in T0 (4.36 μg/L ± 467.05), T1 (0.61 μg/L ± 467.05) and T2 (1.26 μg/L ± 467.05)
     pBMC-BC in T0 (0.08 μg/L ± 467.05), T1 (0.06 μg/L ± 467.05) and T2 (0.10 μg/L ± 467.05)
     Corexit 9500 in T0 (17.72 μg/L ± 467.05), T1 (5.99 μg/L ± 467.05) and T2 (4.99 μg/L ± 467.05)
     oWSF + pBMC-BC in T0 (3.39 μg/L ± 539.30), T1 (0.03 μg/L ± 539.30) and T2 (0.14 μg/L ± 539.30)
     oWSF + Corexit 9500 in T0 (803.19 μg/L ± 467.05), T1 (4665.46 μg/L ± 467.05) and T2 (2711.75 μg/L ± 467.05)
     pBMC-BC + Corexit 9500 in T0 (8.60 μg/L ± 467.05), T1 (9.39 μg/L ± 467.05) and T2 (3.94 μg/L ± 467.05)
     oWSF + pBMC-BC + Corexit 9500 in T0 (1162.94 μg/L ± 467.05), T1 (4559.76 μg/L ± 467.05) and T2 (2165.55 μg/L ± 467.05)
N-alkanes Time 4.84 0.013  
  Treatments 9.98 < 0.0001  
  Time:Treatments 2.21 0.022  
  Post-hoc comparison    Control in T0 (1.63 μg/L ± 467.05), T1 (0.48 μg/L ± 467.05) and T2 (0.58 μg/L ± 467.05)
     oWSF in T0 (4.36 μg/L ± 467.05), T1 (0.61 μg/L ± 467.05) and T2 (1.26 μg/L ± 467.05)
     pBMC-BC in T0 (0.08 μg/L ± 467.05), T1 (0.06 μg/L ± 467.05) and T2 (0.10 μg/L ± 467.05)
     Corexit 9500 in T0 (17.72 μg/L ± 467.05), T1 (5.99 μg/L ± 467.05) and T2 (4.99 μg/L ± 467.05)
     oWSF + pBMC-BC in T0 (3.39 μg/L ± 539.30), T1 (0.03 μg/L ± 539.30) and T2 (0.14 μg/L ± 539.30)
     oWSF + Corexit 9500 in T0 (803.19 μg/L ± 467.05), T1 (4665.46 μg/L ± 467.05) and T2 (2711.75 μg/L ± 467.05)
     pBMC-BC + Corexit 9500 in T0 (8.60 μg/L ± 467.05), T1 (9.39 μg/L ± 467.05) and T2 (3.94 μg/L ± 467.05)
     oWSF + pBMC-BC + Corexit 9500 in T0 (1162.94 μg/L ± 467.05), T1 (4559.76 μg/L ± 467.05) and T2 (2165.55 μg/L ± 467.05)